Phase III Study to Evaluate the Efficacy and Safety of AD-209
NCT ID: NCT06348576
Last Updated: 2024-05-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
280 participants
INTERVENTIONAL
2024-05-20
2025-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Efficacy and Safety of AD-209
NCT05631990
A Study to Evaluate the Efficacy and Safety of AD-224
NCT06291207
Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension
NCT04218552
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy
NCT05931224
Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy
NCT05526703
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Test group
AD-209+AD-2091 Placebo
AD-209
PO, Once daily(QD), 8weeks
AD-2091 Placebo
PO, Once daily(QD), 8weeks
Control group
AD-2091+AD-209 Placebo
AD-2091
PO, Once daily(QD), 8weeks
AD-209 Placebo
PO, Once daily(QD), 8weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AD-209
PO, Once daily(QD), 8weeks
AD-2091
PO, Once daily(QD), 8weeks
AD-209 Placebo
PO, Once daily(QD), 8weeks
AD-2091 Placebo
PO, Once daily(QD), 8weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Other inclusions applied
Exclusion Criteria
* Other exclusions applied
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Addpharma Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chang Gyu Park, M.D., Ph.D
Role: PRINCIPAL_INVESTIGATOR
Korea University Guro Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Korea University Guro Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Chang Gyu Park, M.D., Ph.D
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Chang Gyu Park, M.D., Ph.D
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AD-209P3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.